ArticleJournal of Korean medical science2025
Impact of Prepregnancy Maternal Fasting Glucose Levels on Pregnancy and Neonatal Morbidity in Women With Pregestational Diabetes Mellitus.
Article in Journal of Korean medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundManaging blood glucose levels before conception and during pregnancy is crucial for ensuring optimal maternal and fetal outcomes. However, little is known about the impact of maintaining fasting plasma glucose (FPG) levels within a specific range on pregnancy and neonatal morbidities, especially in women with diabetes mellitus (DM). We aimed to evaluate the effects of maternal prepregnancy FPG levels on pregnancy and neonatal morbidity in women with pregestational DM.
methodsThis retrospective nationwide study included singleton pregnant women diagnosed with DM who underwent health screening. We compared the risk of adverse pregnancy outcomes (APOs) and neonatal morbidity based on prepregnancy FPG levels. Multivariate analyses were performed to estimate odds ratios for the risk of APOs and neonatal morbidity.
resultsA total of 7,542 women were included in the analysis. After adjusting for covariates, as FPG levels increased, there was a tendency for a higher risk of preterm birth, macrosomia, and large-for-gestational-age (LGA) babies. Compared to mothers with FPG levels below 85 mg/dL, pregestational FPG ≥ 126 mg/dL was associated with an increased risk of neonatal morbidities such as transient tachypnea of the newborn (TTN), respiratory distress syndrome (RDS), and neonatal hypoglycemia.
conclusionElevated prepregnancy FPG levels were associated with higher frequencies of preterm birth, macrosomia, and LGA. Neonates born to women with diabetes-range FPG had higher rates of TTN, RDS, and neonatal hypoglycemia. Prospective longitudinal studies incorporating both prepregnancy and gestational glycemic status are needed to establish the causal relationship between glycemic control and pregnancy outcomes in women with diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.